Seasonal Malaria Chemoprevention With Dihydroartemisin Piperaquin vs. Sulfadoxine-pyrimethamin+Amodiaquin
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Seasonal Malaria Chemoprevention (SMC) for children less than five years old is one the high
impact interventions against malaria in sub-Saharan Africa (SSA). Since 2016, the Government
of Mali and partners through the National Malaria Control Program has deployed SMC
countrywide during high malaria transmission season with a total of four (4) rounds per year.
Sulfadoxine-Pyrimethamine (SP) with Amodiaquine (AQ) are the drugs used for SMC. However, SP
is also used for Intermittent preventative treatment (IPTp) for pregnant women while AQ has
been used for decades for treatment of uncomplicated malaria.
The proposed study will examine the effect of SMC with Sulfadoxine+Amodiaquine (SP+AQ)
extension to older age, the efficacy of Dihydroartemisin-Piperaquine (DHA-PQ) when used for
SMC, social, cultural, economic and health systems factors associated with effective
implementation of SMC. The specific aims of this study are to: 1] Assess the effect of SMC
(SP+AQ) on malaria incidence and infection prevalence in different age groups across sites;
2] Study the effect of SMC (DHA-PQ) compared to SMC (SP-AQ) among children less than 10
years; 3] Determine the cost-effectiveness for each treatment regimen; ) 4] Explore factors
determining effective SMC implementation including coverage of children targeted to receive
treatment by community distributors, receipt of a full course of treatment, perception of
medications by parents and health care providers, and sustainability; and 5) Establish a
district based system to identify severe cases.
The expected outcomes of this work, upon completion of our specific aims, include 1)
Recommendations to Malian health officials and other partners for improving implementation of
SMC and alternative drug to SP+AQ for SMC, and 2) Guidelines for routine monitoring of SMC
implementation.
Phase:
Phase 1
Details
Lead Sponsor:
University Clinical Research Center, Mali
Collaborators:
Deakin University Johns Hopkins University Tulane University University of Copenhagen University of South Florida
Treatments:
Amodiaquine Artenimol Dihydroartemisinin Fanasil, pyrimethamine drug combination Pyrimethamine Sulfadoxine